These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 6883157)
41. The economic and human impact of new drugs. Lichtenberg FR J Clin Psychiatry; 2003; 64 Suppl 17():15-8. PubMed ID: 14680422 [TBL] [Abstract][Full Text] [Related]
42. The role of computers in drug utilization review. Rucker TD Am J Hosp Pharm; 1972 Feb; 29(2):128-34. PubMed ID: 5020598 [No Abstract] [Full Text] [Related]
43. [The prescription of drugs in liberal medicine. I]. Ferry J; Karsenty S Cah Sociol Demogr Med; 1973; 13(2):48-54. PubMed ID: 4795979 [No Abstract] [Full Text] [Related]
44. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
45. Restricted drug distribution programs. Gabay MP; Costianis R Am J Health Syst Pharm; 2003 Aug; 60(15):1525-30. PubMed ID: 12951752 [No Abstract] [Full Text] [Related]
46. [What will direct future drug utilization? Rational knowledge or police control?]. Järhult B Lakartidningen; 1995 Dec; 92(49):4662, 4667-9. PubMed ID: 8531516 [No Abstract] [Full Text] [Related]
47. [Prices of pharmaceutical preparations in Denmark until 1645: a study of the legislation for stipulating the consumer price of drugs]. Kruse PR Theriaca; 1991 Oct; 27():3-315. PubMed ID: 11640853 [No Abstract] [Full Text] [Related]
48. [Preclinical documentation for the registration of drugs]. Cantone A Boll Chim Farm; 1971 Oct; 110(10):579-81. PubMed ID: 5143356 [No Abstract] [Full Text] [Related]
49. [The pharmaceutical industry faced with the double challenge of aging]. García-Alvarez C Rev Neurol; 1997 Jul; 25 Suppl 1():S76-82. PubMed ID: 9280673 [No Abstract] [Full Text] [Related]
50. Off label use--label off use? Boos J Ann Oncol; 2003 Jan; 14(1):1-5. PubMed ID: 12488285 [No Abstract] [Full Text] [Related]
51. The prescription drug marketing act: a solution in search of a problem? Angarola RT; Beach JE Food Drug Law J; 1996; 51(1):21-55. PubMed ID: 11794352 [No Abstract] [Full Text] [Related]
52. [Realities and paradoxes]. Morel A Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():1S4. PubMed ID: 11435988 [No Abstract] [Full Text] [Related]
54. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages. Consum Rep; 2003 Feb; 68(2):33-7. PubMed ID: 12516586 [No Abstract] [Full Text] [Related]
55. [The status of a nonpatented drug of which the basic molecule in patented]. Petranker L; Stenger J Ann Pharm Fr; 1975 Nov; 33(11):619-25. PubMed ID: 1231608 [No Abstract] [Full Text] [Related]
56. Redesigner drugs. Dove A Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643 [TBL] [Abstract][Full Text] [Related]
57. [40 years of drugs]. Offerhaus L Ned Tijdschr Geneeskd; 1985 May; 129(18):838-41. PubMed ID: 3894991 [No Abstract] [Full Text] [Related]
59. [Clinical documentation for the registration of drugs]. Ferrari V Boll Chim Farm; 1971 Oct; 110(10):582-3. PubMed ID: 5143357 [No Abstract] [Full Text] [Related]
60. The prescribing of mixtures. Blackmore RJ N Z Med J; 1990 Oct; 103(899):493. PubMed ID: 2216144 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]